• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Active surveillance in metastatic pancreatic neuroendocrine tumors:A 20-year single-institutional experience

    2020-09-18 09:45:34HeLiGaoWenQuanWangHuaXiangXuChunTaoWuHaoLiQuanXingNiXianJunYuLiangLiu
    World Journal of Clinical Cases 2020年17期

    He-Li Gao,Wen-Quan Wang,Hua-Xiang Xu,Chun-Tao Wu,Hao Li,Quan-Xing Ni,Xian-Jun Yu,Liang Liu

    He-Li Gao,Wen-Quan Wang,Hua-Xiang Xu,Chun-Tao Wu,Hao Li,Quan-Xing Ni,Xian-Jun Yu,Liang Liu,Department of Pancreatic Surgery,Fudan University Shanghai Cancer Center,Shanghai 200032,China

    He-Li Gao,Wen-Quan Wang,Hua-Xiang Xu,Chun-Tao Wu,Hao Li,Quan-Xing Ni,Xian-Jun Yu,Liang Liu,Department of Oncology,Shanghai Medical College,Fudan University,Shanghai 200032,China

    He-Li Gao,Wen-Quan Wang,Hua-Xiang Xu,Chun-Tao Wu,Hao Li,Quan-Xing Ni,Xian-Jun Yu,Liang Liu,Shanghai Pancreatic Cancer Institute,Shanghai 200032,China

    He-Li Gao,Wen-Quan Wang,Hua-Xiang Xu,Chun-Tao Wu,Hao Li,Quan-Xing Ni,Xian-Jun Yu,Liang Liu,Pancreatic Cancer Institute,Fudan University,Shanghai 200032,China

    Abstract

    Key words:Pancreatic neuroendocrine tumor;Liver metastasis;Active surveillance;Prognosis;Nomogram

    INTRODUCTION

    Pancreatic neuroendocrine tumors (PanNETs),which account for 31.5% of total gastroenteropancreatic NETs,are the most common form of pancreatic tumors in China[1].About one-fourth of PanNET patients have metastasis at diagnosis[2],and the liver is the most common metastatic site.The prognosis of patients with metastatic PanNETs is heterogeneous and varies widely,from 10 mo to more than 10 years.Multiple lines of systemic treatment are considered the standard of care in metastatic nonfunctioning PanNETs (NF-PanNETs),namely,somatostatin analogs,chemotherapy[3],sunitinib,and everolimus[4].However,systemic therapy may not be essential for every patient with metastatic PanNET.To avoid over-treating indolent asymptomatic tumors,the National Comprehensive Cancer Network guidelines for PanNETs state that,for locoregional advanced disease and/or distant metastasis,tumor marker analysis and screening every 3-12 mo is an option if the patient is asymptomatic,has low tumor burden,and has stable disease[5].However,specific factors that influenced surveillance were not mentioned.In addition,data regarding the period of active surveillance in patients with metastatic PanNET are lacking.

    The benefits of active surveillance have been well established in randomized clinical trials of other metastatic malignancies,such as metastatic renal cell carcinoma (RCC)[6],melanoma[7,8],and metastatic prostate cancer[9,10].In this study,we retrospectively reviewed the clinicopathological data of patients with liver metastatic NF-PanNETs who received active surveillance in our institution over the past 20 years.Additionally,we established a nomogram to predict the suitable characteristics for active surveillance in liver metastatic NF-PanNET patients.

    MATERIALS AND METHODS

    Patient selection

    A retrospective review of the NF-PanNET databases of the Pancreatic Oncology Department,Fudan University Shanghai Cancer Center (FUSCC) was performed.396 PanNET patients with metastasis were evaluated.All patients had histologically confirmed PanNET between 1998 and 2018.Pathology records of all included patients were reviewed by the Pathology Department at the FUSCC.All patients had asymptomatic NF-PanNET with liver metastasis,and patients without treatment were selected.We did not specify any laboratory parameters or comorbidities for eligibility.This research was approved by the hospital ethics committee,and written consent was provided for patient information to be used for research purposes.The study was approved by the FUSCC ethical committee.

    Tumor characteristics

    Data were retrieved from patient medical records and included patient demographics(age and sex),pathology reports (T stage,N stage,tumor grade,Ki-67 index,and differentiation),and radiographical documentation [computed tomography (CT),magnetic resonance imaging (MRI),and somatostatin receptor scintigraphy (SRS)].The tumor burden of liver metastasis was measured using the AW VolumeShare 5 system,and the axis of the liver metastasis was measured using MRI screening.Tumor grading was in accordance with the 2017 World Health Organization classification[11].Tumor TNM staging was based on the 2006 ENETS TNM staging system for patients with PanNETs[12].

    Follow-up and survival

    Follow-up was performedviaoutpatient visit or telephone in October 2018.Patients received an enhanced MRI or CT scan every three months.Study investigators assessed progression according to the Response Evaluation Criteria in Solid Tumors(RECIST) version 1.1[13].The active surveillance time in the study was defined as the time from the start of surveillance to the initiation of systemic therapy or withdrawal of consent.The time to progression (TTP) during surveillance was defined as the interval between the start of surveillance and disease progression as evaluated by RECIST 1.1.Overall survival (OS) was defined as the time of diagnosis to death from any cause or the date of the last follow-up (censor date).The median follow-up time was calculated based on censored observations.

    Statistical analysis

    Categorical variables are presented as frequencies and proportions.Categorical data were compared by means of the Chi Square-test.Median OS and TTP were calculated using Kaplan-Meier curves,with subgroups being compared using the log-rank test.Cox proportional hazard models were performed to identify independent predictors of TTP.Univariate analysis was performed for age,sex,resection of primary tumor,T stage,N stage,the largest axis of the liver metastasis,tumor burden of the liver metastasis.Subsequently,all variables with aPvalue <0.10 were selected for multivariable analysis.Subanalysis was performed to identify predictors of TTP for the different histopathologic subtypes.APvalue <0.05 was considered statistically significant.Data were analyzed using SPSS 24.0 software (SPSS,Chicago,IL,USA).The nomogram and C-index were calculated using R (version 2.12.2;http://rproject.org).

    RESULTS

    Patient characteristics

    The study included 76 patients who received active surveillance during the follow-up period.The decision to choose active surveillance in 66 patients was made jointly by the multidisciplinary team,while 10 out 76 patients choose active surveillance because they refused medical treatment due to the financial burden.Patients were initially diagnosed between August 1998 and February 2018.Demographic and baseline characteristics of the 76 included patients are listed in Table 1.Less than half of the patients (40.8%) were diagnosed as stage I-III at the time of surgery,and had recurrent disease during follow-up.In addition,59.2% of patients were diagnosed with stage IV disease.The median disease-free survival was 31 mo (range:6-132 mo).Over half ofthe patients (59.2%) had liver metastasis at the time of diagnosis.All patients had pathological confirmation of liver metastasis by biopsy.All patients had an Eastern Cooperative Oncology Group performance status of 0 to 2 when active surveillance was initiated.

    Table 1 Clinicopathological characteristics of patients with liver metastatic pancreatic neuroendocrine tumors,n (%)

    Outcomes of NF-PanNET patients under surveillance

    Patients were followed up for a median 42 mo (range:8-240 mo).The median active surveillance time was 14 mo [95% confidence interval (CI):11.13–16.87].Sixty-nine(90.7%) patients met the criteria for RECIST-defined progressive disease (PD) at some point in the study,and the median TTP (mTTP) during surveillance was 10 mo(95%CI:7.23-12.76).Of the 76 patients,66 started systemic therapy during the followup period.However,10 patients with PD refused treatment due to personal orfinancial problems,and 4 of these patients died as a result of disease progression.The median OS for the 10 untreated patients was not reached (range:10-113 mo).The median OS for the whole cohort was also not reached.

    Univariate and multivariate analysis of TTP risk factors

    Univariate analysis of baseline prognostic factors revealed that the following risk factors were significantly associated with TTP during surveillance (Figure 1):Resection of the primary tumor (resectedvsnon-resected:10 movs6 mo,P= 0.002),and T stage(T1-2vsT3-4:12 movs6 mo,P= 0.038).Patients with the largest axis of the liver metastasis ≤ 5 mm had longer mTTP than patients with liver metastasis >5 mm (18 movs7 mo,P= 0.002),also those with a tumor burden of the liver metastasis <0.5% had longer mTTP than patients with a tumor burden >0.5% (15 movs7 mo,P= 0.037).When examining the Ki-67 index of the liver metastases,patients with G1 had a longer TTP than those with G2,but the result was not statistically significant (12 movs10 mo,P= 0.165).In the subgroup with liver metastasis,debulking resection of the primary tumor was also significantly correlated with a longer TTP (15 movs6 mo,P= 0.007),whereas debulking resection (transarterial embolization or ablation) of the liver metastasis showed no relationship with TTP (P>0.05).The axis of liver metastasis was measured by MRI screening (Figure 2).

    In the multivariate analysis,only the largest axis of the liver metastasis [hazard ratio(HR):2.11,95%CI:1.0-4.44;P= 0.049],resection of the primary tumor (HR:2.11,95%CI:1.01-4.39;P= 0.045),and T stage (HR:2.53,95%CI:1.3-4.93;P= 0.006) were independent prognostic factors (Tables 2 and 3).

    Nomogram for TTP risk in metastatic PanNETs

    On the basis of the multivariate analysis,we used a recursive partitioning algorithm to separate patients based on the risk factors (largest axis of metastasis >5 mm,T3-T4,and non-resection of the primary tumor) into a favorable group consisting of patients with no risk factors,an intermediate group consisting of patients with one risk factor,and an unfavorable group consisting of patients with two or three risk factors.The favorable group had an estimated mTTP of 25 mo,whereas the intermediate and unfavorable groups had an estimated mTTP of 10 mo and 6 mo,respectively(Figure 3).The difference was significant (HR:2.545,95%CI:1.65-3.92;P<0.001).

    A prognostic nomogram that combined all three independent predictors for TTP during surveillance of metastatic PanNETs is shown in Figure 4.The C-index of the nomogram for predicting TTP was 0.603 (95%CI:0.47-0.74).Moreover,the calibration plot showed good calibration.

    DISCUSSION

    The findings from our study indicated that active surveillance was a viable strategy in some patients with metastatic NF-PanNETs.The median surveillance period was more than 12 mo,and the mTTP during surveillance was 10 mo.For patients with no risk factors,the mTTP was more than 24 mo.Our multivariate analysis and nomogram also showed that patients with fewer adverse prognostic features should be considered for active surveillance.

    Metastatic PanNET is a disease characterized by a varied natural history.Many prognostic schemas have been developed,leading to a 5-year OS rate of more than 60%[14].Stage,grade,and functionality are all independent factors related to the prognosis of PanNETs[15,16],and some gene mutations are also associated with prognosis,such asMEN1,ATRX/DAXX[17],and genes in themTORpathway[18],indicating the diverse underlying biology of metastatic NF-PanNETs.

    To our knowledge,very little prospective evaluation has been carried out to study surveillance in metastatic NF-PanNETs.However,active surveillance has been used in cases of neuroendocrine neoplasms in other organs.Almost 50% of patients with asymptomatic metastatic pheochromocytomas (PCs) and paragangliomas (PGLs) had stable disease after a year of follow-up[19].It was concluded that selected PC/PGL patients with slowly progressing tumors could safely use the wait-and-see strategy as an option[20].In cases of medullary thyroid carcinoma,patients with low disease volume should be considered for a wait-and-see strategy;only those with a large volume and PD are clear candidates for systemic therapy[21].Treatment strategies for other indolent malignancies also take an active surveillance approach into account.A prospective phase II trial of 52 patients with RCC showed that a subset of patients with metastatic RCC can safely undergo surveillance before starting systemic therapy.Favorable factors include fewer International Metastatic Database Consortium adverse risk factors and fewer organs affected by metastasis[6].A retrospective series of 58 patients with metastatic RCC noted an initial observation period of 12.4 mo until systemic therapy was started[22].For patients with follicular lymphoma with low tumor burden,a study examining a watch-and-wait strategy indicated a median time to starting therapy of 31.1 mo;46% of patients did not need treatment at 3 years,and there was no difference in OS compared to the treatment group[23].

    Table 2 Univariate analysis of risk factors for time to progression in pancreatic neuroendocrine tumors

    Table 3 Multivariate analysis of risk factors for time to progression in pancreatic neuroendocrine tumors

    A surveillance-based approach has been investigated in small NF-PanNETs[24].Surveillance of liver metastatic NF-PanNETs has not been fully evaluated.In the CLARINET trial[25],although 96% of patients had stable disease in the 3 to 6 mo before randomization,mPFS and 24-mo PFS rate were significantly prolonged with lanreotide in comparison with placebo.This result supports that starting SSA therapy before tumor progression may prevent tumor growth.However,our retrospective analysis restaged NF-PanNET patients with liver metastasis and found that,a subset of favorable patients (less 10%) in our cohort,as defined by the largest axis of the liver metastasis <5 mm,T1–T2,and resection of the primary site,showed a TTP of more than 2 years without systemic therapy.This subpopulation may be considered for active surveillance in clinical management,if the patient’s situation allows.Appropriate selection of patients and adequate monitoring are crucial for this approach.In our study,more than 90% patients with risk factors had PD after 6-10 mo,which made them unsuitable for active surveillance and systemic targeted therapy should be started immediately.The exclusion and inclusion criteria in clinical trials may also need to take these factors into account,as patients with favorable factors may have stable disease without any treatment.

    Our study has some limitations.First,it was a retrospective study.We did not have another cohort on which to test the nomogram,and the C-index of the nomogram was not very high.Second,patients in the study were not from a highly selected population.Some patients refused systemic therapy due to financial problems.Furthermore,we did not set a control group of patients with treatment.Nevertheless,prospective assessment of this strategy in selected patients would provide guidance for physicians on how to select appropriate patients for active surveillance.

    In conclusion,our study showed that active surveillance might be an approach for metastatic NF-PanNET patients with favorable risk factors,while other patients with metastatic NF-PanNET progressed rapidly without treatment.Additional investigations into the risks and benefits of surveillance are warranted.

    Figure 1 Determination of the clinicopathological factors predicting time to progression during surveillance of metastatic pancreatic neuroendocrine tumors.A:Tumor burden of liver metastasis;B:Largest axis of the liver metastasis;C:T stage;D:M stage at diagnosis;E:Grade of liver metastasis;F:Grade of the primary tumor;G:Resection/transcatheter arterial chemoembolization of the liver metastasis;H:Resection of the primary tumor;I:Resection of the primary tumor in patients with stage IV disease.PanNET:Pancreatic neuroendocrine tumor;TACE:Transcatheter arterial chemoembolization;PD:Progressive disease.

    Figure 3 Risk stratification for predicting time to progression during surveillance on Kaplan-Meier survival curves of patients with metastatic pancreatic neuroendocrine tumors.PD:Progressive disease.

    Figure 4 Nomogram for predicting time to progression during surveillance of metastatic pancreatic neuroendocrine tumors based on our proposed model.Largest axis of the liver metastasis,T stage,and resection of the primary tumor.PFS:Progression-free survival.

    ARTICLE HIGHLIGHTS

    Research background

    Pancreatic neuroendocrine tumors (PanNETs) are heterogeneous and indolent;the National Comprehensive Cancer Network (NCCN) guidelines state that delaying treatment is an option for PanNET with distant metastasis,if the patient has stable disease.

    Research motivation

    The NCCN did not mention specific factors that influenced surveillance.In addition,data regarding the period of active surveillance in patients with metastatic PanNET are lacking.

    Research objectives

    To describe the factors influencing active surveillance in patients with liver metastatic nonfunctioning PanNETs (NF-PanNETs).

    Research methods

    Clinicopathological characteristics of patients with liver metastatic NF-PanNETs who received active surveillance were collected,and the median time to disease progression (TTP) was measured.

    Research results

    The median TTP (mTTP) was 10 mo in 76 patients with liver metastatic NF-PanNETs.Multivariate analysis showed that the largest axis of the liver metastasis >5 mm (P=0.04),non-resection of the primary tumor (P= 0.024),and T3-T4 stage (P= 0.028) were associated with a shorter TTP.The mTTP in patients with no risk factors was 24 mo,which was significantly longer than that in patients with one (10 mo) or more (6 mo)risk factors (P<0.001).A nomogram with three risk factors showed reasonable calibration,with a C-index of 0.603 (95%CI:0.47–0.74).

    Research conclusions

    Patients with favorable factors had a time to progressive disease of more than two years without systemic treatment;further studies with a larger sample size and a control are required.

    Research perspectives

    Active surveillance may only be safe for metastatic NF-PanNET patients with favorable risk factors,and other patients progressed rapidly without treatment.

    ACKNOWLEDGEMENTS

    We thank Professor Sheng-Jian Zhang,from the Radiology Department of FUSCC,for CT/MRI imaging support,and Ze-Zhou Wang,from the Cancer Prevent Department of FUSCC,for statistics review.

    麻豆乱淫一区二区| 国产精品成人在线| aaaaa片日本免费| 色视频在线一区二区三区| 757午夜福利合集在线观看| 日韩免费av在线播放| 人人妻人人爽人人添夜夜欢视频| 日韩欧美免费精品| 亚洲伊人久久精品综合| 午夜福利视频精品| 久久婷婷成人综合色麻豆| 日韩精品免费视频一区二区三区| 亚洲av第一区精品v没综合| 女警被强在线播放| av国产精品久久久久影院| 日韩中文字幕欧美一区二区| 日韩欧美一区二区三区在线观看 | 成人亚洲精品一区在线观看| 国产熟女午夜一区二区三区| 亚洲欧美日韩高清在线视频 | 亚洲人成电影免费在线| 人人澡人人妻人| 一级黄色大片毛片| 亚洲色图综合在线观看| 麻豆成人av在线观看| 久久国产精品男人的天堂亚洲| 久久国产精品大桥未久av| 91国产中文字幕| 亚洲精品国产色婷婷电影| 欧美日韩av久久| 精品亚洲成国产av| 国产av精品麻豆| 无人区码免费观看不卡 | 肉色欧美久久久久久久蜜桃| 99热网站在线观看| 一区二区三区国产精品乱码| 91字幕亚洲| 日韩三级视频一区二区三区| 中文字幕人妻熟女乱码| 国产精品电影一区二区三区 | 亚洲久久久国产精品| 99riav亚洲国产免费| 欧美中文综合在线视频| 亚洲色图av天堂| 国产又色又爽无遮挡免费看| 高清黄色对白视频在线免费看| 久久久久视频综合| av不卡在线播放| 色在线成人网| 俄罗斯特黄特色一大片| 女人精品久久久久毛片| 中文字幕精品免费在线观看视频| 欧美精品高潮呻吟av久久| 精品国产乱码久久久久久男人| e午夜精品久久久久久久| 亚洲国产欧美网| 亚洲av成人不卡在线观看播放网| 欧美日韩中文字幕国产精品一区二区三区 | 99国产精品一区二区蜜桃av | 两人在一起打扑克的视频| 丰满人妻熟妇乱又伦精品不卡| 国产精品电影一区二区三区 | 啦啦啦视频在线资源免费观看| 热99国产精品久久久久久7| 亚洲国产欧美日韩在线播放| 国产主播在线观看一区二区| 精品久久久久久久毛片微露脸| 中亚洲国语对白在线视频| 午夜精品久久久久久毛片777| 免费不卡黄色视频| 人人澡人人妻人| 精品国产超薄肉色丝袜足j| 欧美老熟妇乱子伦牲交| 中文欧美无线码| 欧美精品av麻豆av| 国产无遮挡羞羞视频在线观看| 18禁国产床啪视频网站| 成人亚洲精品一区在线观看| 精品国产乱码久久久久久小说| 精品午夜福利视频在线观看一区 | 精品人妻在线不人妻| 一级片免费观看大全| 亚洲欧洲日产国产| 国产亚洲av高清不卡| 欧美老熟妇乱子伦牲交| 久久久国产成人免费| 啦啦啦在线免费观看视频4| 丝袜在线中文字幕| 久久精品人人爽人人爽视色| 国产成人免费观看mmmm| 老司机亚洲免费影院| 日韩 欧美 亚洲 中文字幕| 亚洲七黄色美女视频| 自拍欧美九色日韩亚洲蝌蚪91| 手机成人av网站| 人妻 亚洲 视频| 午夜福利在线观看吧| 中文字幕最新亚洲高清| 老汉色∧v一级毛片| 日本黄色日本黄色录像| 99久久国产精品久久久| 午夜福利影视在线免费观看| 久久狼人影院| 1024视频免费在线观看| 国产成人av激情在线播放| 亚洲精品在线美女| 99在线人妻在线中文字幕 | 少妇猛男粗大的猛烈进出视频| 自线自在国产av| 亚洲九九香蕉| 亚洲精品国产一区二区精华液| av免费在线观看网站| 国产一卡二卡三卡精品| 欧美乱妇无乱码| 精品国内亚洲2022精品成人 | 日本欧美视频一区| 亚洲一区二区三区欧美精品| 色视频在线一区二区三区| 999久久久国产精品视频| 国产一区二区三区在线臀色熟女 | 99热国产这里只有精品6| 亚洲av成人一区二区三| 搡老岳熟女国产| 69av精品久久久久久 | 90打野战视频偷拍视频| 大码成人一级视频| 亚洲三区欧美一区| 久久精品人人爽人人爽视色| 色综合欧美亚洲国产小说| 九色亚洲精品在线播放| 91精品三级在线观看| 99久久国产精品久久久| 色老头精品视频在线观看| 日韩欧美一区二区三区在线观看 | 夜夜夜夜夜久久久久| 欧美国产精品va在线观看不卡| 午夜福利乱码中文字幕| 国产av又大| 亚洲国产欧美网| 国产真人三级小视频在线观看| 电影成人av| 久久热在线av| 亚洲 国产 在线| 肉色欧美久久久久久久蜜桃| 伦理电影免费视频| 999久久久国产精品视频| 肉色欧美久久久久久久蜜桃| 亚洲欧洲精品一区二区精品久久久| 不卡一级毛片| 久久国产精品大桥未久av| 熟女少妇亚洲综合色aaa.| 中文亚洲av片在线观看爽 | bbb黄色大片| 我要看黄色一级片免费的| 欧美黑人精品巨大| 午夜精品久久久久久毛片777| 欧美乱码精品一区二区三区| 午夜福利乱码中文字幕| 99精品久久久久人妻精品| 91九色精品人成在线观看| av欧美777| 中文欧美无线码| 午夜91福利影院| h视频一区二区三区| 国产精品成人在线| 日韩免费高清中文字幕av| 两个人免费观看高清视频| 欧美成狂野欧美在线观看| 丝袜美足系列| 人妻 亚洲 视频| av福利片在线| 色老头精品视频在线观看| 美女高潮喷水抽搐中文字幕| 色婷婷av一区二区三区视频| 久久国产精品影院| 国产免费现黄频在线看| 国产精品免费大片| 午夜精品国产一区二区电影| 亚洲一码二码三码区别大吗| av国产精品久久久久影院| tube8黄色片| 一边摸一边抽搐一进一小说 | 自线自在国产av| 久久99一区二区三区| 9色porny在线观看| 亚洲国产毛片av蜜桃av| 国产黄频视频在线观看| 国产在视频线精品| 欧美黄色片欧美黄色片| 夜夜夜夜夜久久久久| 亚洲欧美日韩另类电影网站| 国产免费现黄频在线看| 欧美黄色淫秽网站| 成人永久免费在线观看视频 | 亚洲一码二码三码区别大吗| 免费不卡黄色视频| 丰满少妇做爰视频| 亚洲精品一卡2卡三卡4卡5卡| 每晚都被弄得嗷嗷叫到高潮| 久久久国产欧美日韩av| 女性生殖器流出的白浆| 久久久久久久久久久久大奶| 亚洲成a人片在线一区二区| 黄色a级毛片大全视频| 97人妻天天添夜夜摸| 不卡一级毛片| av线在线观看网站| 精品视频人人做人人爽| 天天操日日干夜夜撸| 久久国产精品人妻蜜桃| 国产野战对白在线观看| 中文欧美无线码| 又黄又粗又硬又大视频| 久久久久精品人妻al黑| 欧美日韩亚洲国产一区二区在线观看 | 一区二区三区乱码不卡18| 考比视频在线观看| 久久久久久亚洲精品国产蜜桃av| 在线观看www视频免费| 久久中文字幕人妻熟女| 人人澡人人妻人| 亚洲国产毛片av蜜桃av| 精品熟女少妇八av免费久了| 一二三四在线观看免费中文在| 日韩熟女老妇一区二区性免费视频| 精品欧美一区二区三区在线| 老熟妇仑乱视频hdxx| 国产成人精品无人区| 亚洲色图综合在线观看| 少妇被粗大的猛进出69影院| 两人在一起打扑克的视频| 日韩中文字幕欧美一区二区| 在线看a的网站| 亚洲色图综合在线观看| 午夜福利一区二区在线看| 亚洲国产av影院在线观看| 国产亚洲av高清不卡| 欧美激情高清一区二区三区| 国产99久久九九免费精品| 亚洲欧美色中文字幕在线| 如日韩欧美国产精品一区二区三区| 热99国产精品久久久久久7| 成年人免费黄色播放视频| 成人三级做爰电影| 波多野结衣一区麻豆| 又黄又粗又硬又大视频| 亚洲精品粉嫩美女一区| 久久久精品94久久精品| 免费黄频网站在线观看国产| 在线观看免费午夜福利视频| 亚洲欧美日韩另类电影网站| 亚洲国产精品一区二区三区在线| 亚洲中文日韩欧美视频| 免费在线观看完整版高清| 一本—道久久a久久精品蜜桃钙片| 久久久精品区二区三区| 大型av网站在线播放| 91精品国产国语对白视频| 日韩欧美一区视频在线观看| 免费在线观看黄色视频的| 国产精品一区二区精品视频观看| 国产有黄有色有爽视频| 国产成人免费无遮挡视频| 精品人妻在线不人妻| 最新在线观看一区二区三区| 少妇粗大呻吟视频| 在线观看免费日韩欧美大片| 国产精品1区2区在线观看. | 欧美日韩成人在线一区二区| 下体分泌物呈黄色| 天堂中文最新版在线下载| 一级毛片精品| 一本一本久久a久久精品综合妖精| 成人三级做爰电影| 色在线成人网| 久久这里只有精品19| 精品国产超薄肉色丝袜足j| 久久久久久久精品吃奶| 高清欧美精品videossex| 亚洲精品国产精品久久久不卡| 国产高清国产精品国产三级| 在线观看免费视频网站a站| 老司机午夜十八禁免费视频| 免费在线观看影片大全网站| 黄片大片在线免费观看| 亚洲专区国产一区二区| 男女下面插进去视频免费观看| 精品卡一卡二卡四卡免费| 91精品三级在线观看| 丰满人妻熟妇乱又伦精品不卡| 一个人免费看片子| 亚洲人成伊人成综合网2020| 亚洲国产欧美日韩在线播放| 国产精品成人在线| 麻豆乱淫一区二区| 男女边摸边吃奶| 国产精品熟女久久久久浪| 日韩熟女老妇一区二区性免费视频| 两个人看的免费小视频| 午夜福利一区二区在线看| 老司机午夜福利在线观看视频 | 嫁个100分男人电影在线观看| 欧美精品啪啪一区二区三区| 中文字幕另类日韩欧美亚洲嫩草| 真人做人爱边吃奶动态| 十八禁网站免费在线| svipshipincom国产片| 欧美精品高潮呻吟av久久| 久久这里只有精品19| 老司机靠b影院| 99riav亚洲国产免费| 9热在线视频观看99| 国产亚洲精品久久久久5区| 黄色毛片三级朝国网站| 亚洲精品美女久久久久99蜜臀| 国产精品欧美亚洲77777| 天天影视国产精品| 成年女人毛片免费观看观看9 | 欧美黑人精品巨大| 高清av免费在线| 少妇精品久久久久久久| av片东京热男人的天堂| 99国产极品粉嫩在线观看| 一区在线观看完整版| 亚洲欧美激情在线| 亚洲av国产av综合av卡| 亚洲欧美精品综合一区二区三区| 老鸭窝网址在线观看| 老司机亚洲免费影院| 久久人妻福利社区极品人妻图片| 9191精品国产免费久久| 精品久久久久久久毛片微露脸| 窝窝影院91人妻| 99国产精品免费福利视频| 国产精品一区二区在线不卡| 另类亚洲欧美激情| 国产人伦9x9x在线观看| 国产欧美日韩一区二区三| 美女扒开内裤让男人捅视频| 国产xxxxx性猛交| 国产97色在线日韩免费| 久久久国产欧美日韩av| 久久久久视频综合| 国产xxxxx性猛交| 中文字幕色久视频| 巨乳人妻的诱惑在线观看| 99热网站在线观看| 丁香六月天网| 久久久久视频综合| 99re在线观看精品视频| 大片电影免费在线观看免费| 精品一区二区三卡| 亚洲avbb在线观看| av欧美777| 2018国产大陆天天弄谢| 国产淫语在线视频| 别揉我奶头~嗯~啊~动态视频| 在线十欧美十亚洲十日本专区| 两个人免费观看高清视频| 制服诱惑二区| 无限看片的www在线观看| 美女高潮到喷水免费观看| 日本av手机在线免费观看| 99re6热这里在线精品视频| 中文字幕最新亚洲高清| 美女高潮喷水抽搐中文字幕| 亚洲精品久久午夜乱码| 啦啦啦 在线观看视频| 青青草视频在线视频观看| 人妻一区二区av| 国产aⅴ精品一区二区三区波| 久久精品国产亚洲av香蕉五月 | 在线 av 中文字幕| 色精品久久人妻99蜜桃| 国产日韩欧美视频二区| 高清毛片免费观看视频网站 | 欧美精品av麻豆av| 人人妻人人爽人人添夜夜欢视频| 看免费av毛片| 国产午夜精品久久久久久| av国产精品久久久久影院| 在线天堂中文资源库| 国产99久久九九免费精品| 日韩三级视频一区二区三区| 大片免费播放器 马上看| 人人妻人人澡人人爽人人夜夜| 亚洲国产欧美网| 黄色视频,在线免费观看| 中文字幕高清在线视频| 国产有黄有色有爽视频| 成年人午夜在线观看视频| 日本a在线网址| 五月天丁香电影| 久久久久久久精品吃奶| 亚洲五月色婷婷综合| 视频在线观看一区二区三区| 999久久久精品免费观看国产| 成人手机av| 999久久久精品免费观看国产| 后天国语完整版免费观看| 国产一区二区三区视频了| 久久久国产成人免费| 中文字幕制服av| 日韩有码中文字幕| 久久精品国产a三级三级三级| aaaaa片日本免费| 久久久国产欧美日韩av| 精品午夜福利视频在线观看一区 | 极品人妻少妇av视频| 精品亚洲成a人片在线观看| 在线av久久热| 成年动漫av网址| 成人18禁在线播放| 91精品三级在线观看| 日日爽夜夜爽网站| 99国产综合亚洲精品| 午夜福利视频精品| 黄频高清免费视频| 欧美日韩精品网址| 嫁个100分男人电影在线观看| 亚洲精品国产区一区二| 女警被强在线播放| 天天躁狠狠躁夜夜躁狠狠躁| 国产男女内射视频| 亚洲,欧美精品.| 精品一区二区三区av网在线观看 | 黄色怎么调成土黄色| 在线天堂中文资源库| 热re99久久国产66热| 欧美激情高清一区二区三区| 午夜激情av网站| 亚洲av国产av综合av卡| 欧美日韩亚洲高清精品| 日韩一卡2卡3卡4卡2021年| 精品亚洲成国产av| 欧美日韩亚洲国产一区二区在线观看 | 伊人久久大香线蕉亚洲五| 国产男靠女视频免费网站| 99热网站在线观看| 在线观看免费视频网站a站| 制服人妻中文乱码| 在线天堂中文资源库| 亚洲av成人一区二区三| 亚洲一码二码三码区别大吗| 久久久精品区二区三区| 三级毛片av免费| 一个人免费看片子| 一级毛片电影观看| 在线天堂中文资源库| 9191精品国产免费久久| 香蕉丝袜av| 一边摸一边抽搐一进一出视频| 色精品久久人妻99蜜桃| 飞空精品影院首页| 首页视频小说图片口味搜索| 欧美变态另类bdsm刘玥| 日本av手机在线免费观看| 91成年电影在线观看| 欧美 亚洲 国产 日韩一| 欧美精品人与动牲交sv欧美| 精品国产亚洲在线| 午夜老司机福利片| 国产不卡一卡二| 亚洲欧洲精品一区二区精品久久久| 亚洲成av片中文字幕在线观看| 美女福利国产在线| 日本a在线网址| 国产亚洲av高清不卡| 99精品久久久久人妻精品| 国产野战对白在线观看| 丰满人妻熟妇乱又伦精品不卡| 亚洲久久久国产精品| 午夜日韩欧美国产| cao死你这个sao货| 国产一区二区三区视频了| 精品久久久久久电影网| 亚洲国产看品久久| 9色porny在线观看| 精品国产一区二区三区久久久樱花| www日本在线高清视频| 国产成人影院久久av| 少妇粗大呻吟视频| 精品欧美一区二区三区在线| 午夜福利,免费看| 精品少妇内射三级| 亚洲一码二码三码区别大吗| 久久久久久免费高清国产稀缺| 国产麻豆69| 精品视频人人做人人爽| 看免费av毛片| 51午夜福利影视在线观看| 黑人巨大精品欧美一区二区mp4| 欧美日韩福利视频一区二区| 国产xxxxx性猛交| 久久热在线av| 国产精品av久久久久免费| 亚洲欧美精品综合一区二区三区| 99热国产这里只有精品6| 搡老岳熟女国产| 丰满迷人的少妇在线观看| 亚洲av电影在线进入| a级毛片黄视频| 如日韩欧美国产精品一区二区三区| 精品人妻1区二区| 法律面前人人平等表现在哪些方面| 国产欧美日韩精品亚洲av| 欧美乱码精品一区二区三区| 亚洲av国产av综合av卡| 亚洲伊人色综图| 国产激情久久老熟女| 国产欧美日韩精品亚洲av| 无限看片的www在线观看| 亚洲人成电影观看| 亚洲伊人色综图| 久久久精品94久久精品| 90打野战视频偷拍视频| 黄色成人免费大全| 无人区码免费观看不卡 | 脱女人内裤的视频| 狠狠狠狠99中文字幕| 动漫黄色视频在线观看| 在线av久久热| 男女床上黄色一级片免费看| 夜夜骑夜夜射夜夜干| 超色免费av| 男女午夜视频在线观看| 国产精品一区二区在线不卡| 99精国产麻豆久久婷婷| 亚洲熟女毛片儿| 亚洲成a人片在线一区二区| 久久久欧美国产精品| 美女福利国产在线| 男女边摸边吃奶| 伊人久久大香线蕉亚洲五| 法律面前人人平等表现在哪些方面| 岛国毛片在线播放| 精品福利观看| 99热国产这里只有精品6| avwww免费| 久久 成人 亚洲| 人成视频在线观看免费观看| 狠狠精品人妻久久久久久综合| 国产精品久久电影中文字幕 | 亚洲一码二码三码区别大吗| 欧美日韩亚洲高清精品| 国产精品久久电影中文字幕 | 国产福利在线免费观看视频| 亚洲国产欧美日韩在线播放| 欧美另类亚洲清纯唯美| 女性生殖器流出的白浆| 久热爱精品视频在线9| 日本wwww免费看| 国产av一区二区精品久久| 亚洲欧美日韩高清在线视频 | 不卡一级毛片| 人妻久久中文字幕网| 老汉色av国产亚洲站长工具| www日本在线高清视频| 99香蕉大伊视频| 亚洲精品久久成人aⅴ小说| 一区二区三区国产精品乱码| 国产黄色免费在线视频| 91成人精品电影| 国产人伦9x9x在线观看| 国产在线视频一区二区| 久久精品国产综合久久久| 黄频高清免费视频| 亚洲午夜理论影院| 国产成人精品在线电影| 午夜福利影视在线免费观看| 男女下面插进去视频免费观看| 美女国产高潮福利片在线看| 久久精品成人免费网站| 精品卡一卡二卡四卡免费| 国产亚洲精品久久久久5区| 久久久久网色| 亚洲色图 男人天堂 中文字幕| 欧美在线黄色| 一区二区三区国产精品乱码| 这个男人来自地球电影免费观看| 精品亚洲成国产av| 一级毛片女人18水好多| 国产精品 国内视频| 老熟女久久久| 9色porny在线观看| 国产成人精品久久二区二区91| 三上悠亚av全集在线观看| 国产精品 欧美亚洲| 99精国产麻豆久久婷婷| 婷婷成人精品国产| 亚洲avbb在线观看| 精品久久久久久久毛片微露脸| 成人特级黄色片久久久久久久 | 成人国产一区最新在线观看| 国产高清国产精品国产三级| 免费女性裸体啪啪无遮挡网站| 久久婷婷成人综合色麻豆| 亚洲欧洲日产国产| 精品国产一区二区三区久久久樱花| 不卡一级毛片| 午夜成年电影在线免费观看| 亚洲av电影在线进入| 久久久久久免费高清国产稀缺| 欧美另类亚洲清纯唯美| 久久国产精品大桥未久av| 欧美日韩黄片免| 777米奇影视久久| 色94色欧美一区二区| 日韩中文字幕欧美一区二区| 成人三级做爰电影| 午夜福利在线免费观看网站| 激情视频va一区二区三区| 熟女少妇亚洲综合色aaa.| 99精国产麻豆久久婷婷| 黄色 视频免费看|